Iodixanol vs iopamidol in intravenous DSA of the abdominal aorta and lower extremity arteries: a comparative phase-III trial

Iodixanol (Visipaque, 320 mgI/ml) was compared with iopamidol (Solutrast, 370 mgI/ml) in a double-blind, randomized, parallel group, intravenous DSA phase-III trial for evaluation of safety and efficacy. A total of 117 patients received iodixanol (n = 60) or iopamidol (n = 57). Diagnostic efficacy w...

Full description

Saved in:
Bibliographic Details
Published in:European radiology 1996, Vol.6 (1), p.9-13
Main Authors: Fischbach, R, Landwehr, P, Lackner, K, Nossen, J O, Heindel, W, Berg, K J, Eichhorn, G, Jacobsen, T F
Format: Article
Language:English
Subjects:
Acetylglucosaminidase - urine
Adult
Angiography, Digital Subtraction - adverse effects
Aorta, Abdominal - diagnostic imaging
Aortography
Arteries
Contrast Media - administration & dosage
Contrast Media - adverse effects
Contrast Media - analysis
Creatinine - blood
Creatinine - urine
Double-Blind Method
Female
Humans
Injections, Intravenous
Iodine - analysis
Iopamidol - administration & dosage
Iopamidol - adverse effects
Iopamidol - analysis
Kidney - drug effects
Kidney - enzymology
Leg - blood supply
Male
Middle Aged
Pain - etiology
Safety
Sensation
Triiodobenzoic Acids - administration & dosage
Triiodobenzoic Acids - adverse effects
Triiodobenzoic Acids - analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Iodixanol (Visipaque, 320 mgI/ml) was compared with iopamidol (Solutrast, 370 mgI/ml) in a double-blind, randomized, parallel group, intravenous DSA phase-III trial for evaluation of safety and efficacy. A total of 117 patients received iodixanol (n = 60) or iopamidol (n = 57). Diagnostic efficacy was evaluated using categoric and visual analogue scales. Discomfort and adverse events were recorded. A total of 39 patients collected urine up to 72 h after the examination for analysis. Diagnostic efficacy and radiographic density were similar in both groups. Discomfort was milder with iodixanol. The difference between the frequency of adverse events between both groups (iodixanol = 7, iopamidol = 2) was without statistical significance. Creatinine clearance was slightly more affected by iodixanol, whereas the increase in renal excretion of N-acetyl-beta-glucosaminidase (NAG) in the first 24-h collection period after the examination was significantly higher (p < 0.01) with iopamidol. Iodixanol was of equal diagnostic efficacy compared with iopamidol despite its reduced iodine content. Both contrast media are well suited for IV DSA.
ISSN:0938-7994
1432-1084
DOI:10.1007/BF00619943